https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30808 Wed 11 Apr 2018 12:31:21 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51488 Thu 07 Sep 2023 10:52:02 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:10956 Sat 24 Mar 2018 08:14:14 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28752 Sat 24 Mar 2018 07:37:36 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46873 7. Overall positive surgical margins (PSM) occurred in 15.9% with pT2 PSM 9.8%, pT3a PSM 30.8% and pT3b PSM 39.2%. Mean urinary continence at 12 months was 91.4% (data available from five surgeons). Mean 12 months potency after bilateral nerve spare was 47.2% (data available from four surgeons). Biochemical recurrence occurred in 10.6% (mean follow up 17 months). Conclusion: The Australian experience of Fellowship trained surgeons performing LRP demonstrates favourable peri-operative, oncological and functional outcomes in comparison to published data for open, laparoscopic and robotic assisted radical prostatectomy. In our Australian centres, LRP remains an acceptable minimally invasive surgical treatment for prostate cancer despite the increasing use of robotic assisted surgery.]]> Mon 05 Dec 2022 09:22:03 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45705 Fri 04 Nov 2022 08:48:56 AEDT ]]>